Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 11;14:1118397. doi: 10.3389/fphar.2023.1118397

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Li, He, Li, Xiong, Peng, Wang, Zhuo, Jiang, Lu and Wang.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Compound F8·2HCl suppressed gastric xenograft tumor growth in vivo. Male BALB/c nude mice were divided into five groups (n = 6 per group) including vehicle group, apatinib (positive drug) at 37.5 mg/kg dose, compound F8·2HCl at 37.5 mg/kg dose, compound F8·2HCl at 75 mg/kg dose and administrated via oral gavage twice daily for 15 days. (A) Tumor volumes plotted as mean ± SEM. (B) Mice weight curve during treatment plotted as mean ± SD. (C,D) Tumor weight and size on the final day. Statistical analyses showed the mean ± SD or SEM of three independent experiments, comparing each treatment group to the blank and apatinib group: (*) p < 0.05, (**) p < 0.01, (***) p < 0.001.